EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Addressing the key issue: Antigen-specific targeting of B cells in autoimmune diseases

Miles D Holborough-Kerkvliet, Sanne Kroos, Renee van de Wetering, René E M Toes

Immunology Letters · 2023-07 · 259 · 37-45

DOI: 10.1016/j.imlet.2023.05.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunology Letters, 2023-07. Verfasst von Miles D Holborough-Kerkvliet und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. Hauptthemen laut MEDLINE: Autoimmune Diseases, Arthritis, Rheumatoid. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NWO, European Research Council, ReumaNederland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Autoimmune diseases are heterogeneous pathologies characterized by a breakdown of immunological tolerance to self, resulting in a chronic and aberrant immune response to self-antigens. The scope and extent of affected tissues can vary greatly per autoimmune disease and can involve multiple organs and tissue types. The pathogenesis of most autoimmune diseases remains unknown but it is widely accepted that a complex interplay between (autoreactive) B and T cells in the context of breached immunological tolerance drives autoimmune pathology. The importance of B cells in autoimmune disease is exemplified by the successful use of B cell targeting therapies in the clinic. For example, Rituximab, a depleting anti-CD20 antibody, has shown favorable results in reducing the signs and symptoms of multiple autoimmune diseases, including Rheumatoid Arthritis, Anti-Neutrophil Cytoplasmic Antibody associated vasculitis and Multiple Sclerosis. However, Rituximab depletes the entire B cell repertoire, leaving patients susceptible to (latent) infections. Therefore, multiple ways to target autoreactive cells in an antigen-specific manner are currently under investigation. In this review, we will lay out the current state of antigen-specific B cell inhibiting or depleting therapies in the context of autoimmune diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Autoimmune DiseasesArthritis, RheumatoidHumansRituximabAutoimmunityB-Lymphocytes

Stichwörter der Autor:innen

Antigen-specificAutoantibodyAutoimmunityAutoreactivityB cellsTolerance

Substanzen

Rituximab

Autor:innen und Institutionen

  • Department of Rheumatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands.
  • Department of Rheumatology, Leiden University Medical Center, Albinusdreef 2, 2333 ZA, Leiden, The Netherlands. Electronic address: s.kroos@lumc.nl.

Förderung

  • NWO
  • European Research Council
  • ReumaNederland

Zitieren

APA

Holborough-Kerkvliet, M. D., Kroos, S., van de Wetering, R., & Toes, R. E. M. (2023). Addressing the key issue: Antigen-specific targeting of B cells in autoimmune diseases. Immunology Letters, 259, 37-45. https://doi.org/10.1016/j.imlet.2023.05.005

Vancouver

Holborough-Kerkvliet MD, Kroos S, van de Wetering R, Toes REM. Addressing the key issue: Antigen-specific targeting of B cells in autoimmune diseases. Immunology Letters. 2023;259:37-45. doi:10.1016/j.imlet.2023.05.005

BibTeX
@article{HolboroughKerkvliet2023,
  author = {Holborough-Kerkvliet, Miles D and Kroos, Sanne and van de Wetering, Renee and Toes, René E M},
  title = {Addressing the key issue: Antigen-specific targeting of B cells in autoimmune diseases},
  journal = {Immunology Letters},
  year = {2023},
  volume = {259},
  pages = {37--45},
  doi = {10.1016/j.imlet.2023.05.005}
}
Kostenlos starten →